{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:09:15Z","timestamp":1795194555586,"version":"4.10.3"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["19-73-30017"],"award-info":[{"award-number":["19-73-30017"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ijbiomac.2022.07.137","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T22:54:04Z","timestamp":1658444044000},"page":"775-798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Cross reacting material (CRM197) as a carrier protein for carbohydrate conjugate vaccines targeted at bacterial and fungal pathogens"],"prefix":"10.1016","volume":"218","author":[{"given":"E.A.","family":"Khatuntseva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.E.","family":"Nifantiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0005","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1021\/acs.chemrev.0c01210","article-title":"Discovery of semi- and fully-synthetic carbohydrate vaccines against bacterial infections using a medicinal chemistry approach","volume":"121","author":"Seeberger","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0010","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1042\/BST20210766","article-title":"Semi- and fully synthetic carbohydrate vaccines against pathogenic bacteria: recent developments","volume":"49","author":"Zas\u0142ona","year":"2021","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10719-021-09990-y","article-title":"Carbohydrate based meningococcal vaccines: past and present overview","volume":"38","author":"Berti","year":"2021","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41579-020-00506-3","article-title":"The role of vaccines in combatting antimicrobial resistance","volume":"19","author":"Micoli","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12929-019-0591-0","article-title":"Synthetic carbohydrate-based vaccines: challenges and opportunities","volume":"27","author":"Mettu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ddtec.2020.11.002","article-title":"Synthetic carbohydrate based anti-fungal vaccines","volume":"35\u201336","author":"Krylov","year":"2020","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0035","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/14760584.2019.1657012","article-title":"Glycoconjugate vaccines: current approaches towards faster vaccine design","volume":"18","author":"Micoli","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.biopha.2018.10.075","article-title":"Fungal vaccines, mechanism of actions and immunology: a comprehensive review","volume":"109","author":"Nami","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat4615","article-title":"Glycoconjugate vaccines: principles and mechanisms","volume":"10","author":"Rappuoli","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0050","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/femsre\/fuy011","article-title":"Potential targets for next generation antimicrobial glycoconjugate vaccines","volume":"42","author":"Micoli","year":"2018","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0055","doi-asserted-by":"crossref","first-page":"9015","DOI":"10.1039\/C8CS00495A","article-title":"Antimicrobial glycoconjugate vaccines: an overview of classic and modern approaches for protein modification","volume":"47","author":"Berti","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/vaccines5010004","article-title":"From immunologically archaic to neoteric glycovaccines","volume":"5","author":"Cavallari","year":"2017","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0065","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1002\/chem.201603599","article-title":"An overview of structural features of antibacterial glycoconjugate vaccines that influence their immunogenicity","volume":"23","author":"Khatun","year":"2017","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0070","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/acs.accounts.7b00106","article-title":"Advancing homogeneous antimicrobial glycoconjugate vaccines","volume":"50","author":"Adamo","year":"2017","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0075","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/14712598.2015.993375","article-title":"Glycoconjugate vaccines: an update","volume":"15","author":"Vella","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1134\/S1068162021010106","article-title":"Glycoconjugate vaccines for prevention of haemophilus influenzae type b diseases","volume":"47","author":"Khatuntseva","year":"2021","journal-title":"Russ. J. Bioorg. Chem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006454-199102000-00004","article-title":"Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children","volume":"10","author":"Black","year":"1991","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0090","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.4049\/jimmunol.137.4.1181","article-title":"Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant","volume":"137","author":"Anderson","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0095","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1084\/jem.152.2.361","article-title":"Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates","volume":"152","author":"Schneerson","year":"1980","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0100","doi-asserted-by":"crossref","first-page":"B10","DOI":"10.1016\/j.vaccine.2011.12.060","article-title":"History of meningococcal vaccines and their serological correlates of protection","volume":"30","author":"Vipond","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.micpath.2013.02.003","article-title":"Neisseria meningitidis serogroup B vaccine development","volume":"57","author":"Caesar","year":"2013","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0110","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0264-410X(92)90091-W","article-title":"Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C","volume":"10","author":"Costantino","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial","volume":"299","author":"Snape","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0120","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/adc.2006.111500","article-title":"Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines","volume":"92","author":"Pace","year":"2007","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0125","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.3390\/vaccines6010012","article-title":"Meningococcal vaccines: current status and emerging strategies","volume":"6","author":"McCarthy","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.carres.2021.108277","article-title":"Bacterial surface capsular polysaccharides from Streptococcus pneumoniae: a systematic review on structures, syntheses, and glycoconjugate vaccines","volume":"502","author":"Javed","year":"2021","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0135","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/CMR.00024-15","article-title":"Pneumococcal capsules and their types: past, present, and future","volume":"28","author":"Geno","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1469-0691.2012.03943.x","article-title":"A century of pneumococcal vaccination research in humans","volume":"18","author":"Grabenstein","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1749-6632.2012.06673.x","article-title":"Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine","volume":"1263","author":"Gruber","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0150","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1586\/erv.09.113","article-title":"10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: synflorix","volume":"8","author":"Prymula","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0155","doi-asserted-by":"crossref","first-page":"C26","DOI":"10.1016\/j.vaccine.2011.06.104","article-title":"Prevenar experience","volume":"29","author":"Arguedas","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1134\/S1068162021010076","article-title":"Synthetic analogs of Streptococcus pneumoniae capsular polysaccharides and immunogenic activities of glycoconjugates","volume":"47","author":"Gening","year":"2021","journal-title":"Russ. J. Bioorg. Chem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0165","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1070\/RCR4574","article-title":"Development of approaches to a third-generation carbohydrate-conjugate vaccine against Streptococcus pneumoniae: the search for optimal oligosaccharide ligands","volume":"84","author":"Gening","year":"2015","journal-title":"Russ. Chem. Rev."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0170","doi-asserted-by":"crossref","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ddtec.2020.09.002","article-title":"Broadly protective semi-synthetic glycoconjugate vaccine against pathogens capable of producing poly-\u03b2-(1\u21926)-N-acetyl-d-glucosamine exopolysaccharide","volume":"35\u201336","author":"Gening","year":"2020","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0180","doi-asserted-by":"crossref","first-page":"E2209","DOI":"10.1073\/pnas.1303573110","article-title":"Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens","volume":"110","author":"Cywes-Bentley","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0185","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/IAI.01093-09","article-title":"Synthetic \u03b2(1\u21926)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens","volume":"78","author":"Gening","year":"2010","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0190","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.carres.2006.08.010","article-title":"Synthesis of beta-(1\u21926)-linked glucosamine oligosaccharides corresponding to fragments of the bacterial surface polysaccharide poly-N-acetylglucosamine","volume":"342","author":"Gening","year":"2007","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0195","first-page":"1","article-title":"Vaccines for human fungal diseases: close but still a long way to go","volume":"6","author":"Oliveira","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0200","series-title":"Carbohydrate-based Vaccines: Methods and Protocols. Methods in Molecular Biology","first-page":"11","article-title":"Glycans as vaccine antigens and adjuvants: immunological considerations","author":"Zimmermann","year":"2015"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0205","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1084\/jem.54.3.295","article-title":"On the specificity of serological reactions with simple chemical compounds (inhibition reactions)","volume":"54","author":"Landsteiner","year":"1931","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0210","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/molecules23061451","article-title":"Protein carriers for glycoconjugate vaccines: history, selection criteria, characterization and new trends","volume":"23","author":"Micoli","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0215","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2017.04.078","article-title":"Polysaccharide conjugate vaccine protein carriers as a \u201cneglected valency\u201d - potential and limitation","volume":"35","author":"Br\u00f6ker","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0220","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: characteristics, development, and clinical trials","volume":"9","author":"Pichichero","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0225","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1016\/S0021-9258(19)43810-6","article-title":"Diphtheria toxin and related proteins. I. Isolation and properties of mutant proteins serologically related to diphtheria toxin","volume":"248","author":"Uchida","year":"1973","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0230","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/biot.201400395","article-title":"Outer membrane vesicles as platform vaccine technology","volume":"10","author":"van der Pol","year":"2015","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0235","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1086\/527396","article-title":"Protein D ofHaemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines","volume":"46","author":"Forsgren","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0240","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1016\/j.vaccine.2013.07.078","article-title":"Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines","volume":"31","author":"Tontini","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0245","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1016\/j.vaccine.2010.04.072","article-title":"Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use","volume":"28","author":"Shinefield","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0250","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/21645515.2015.1086048","article-title":"Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and cross reacting material 197 (CRM197) when used as carrier proteins in glycoconjugates","volume":"12","author":"Br\u00f6ker","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0255","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180238","article-title":"Structural and immunological characterization of E. coli derived recombinant CRM197 protein used as carrier in conjugate vaccines","volume":"38","author":"Mishra","year":"2018","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0260","doi-asserted-by":"crossref","first-page":"1700168","DOI":"10.1002\/biot.201700168","article-title":"High-yield production of recombinant CRM197, a non-toxic mutant of diphtheria toxin, in the periplasm of Escherichia coli","volume":"12","author":"Goffin","year":"2017","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0265","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1128\/aem.46.3.560-564.1983","article-title":"Isolation and characterization of Corynebacterium diphtheriae nontandem double lysogens hyperproducing CRM197","volume":"46","author":"Rappuoli","year":"1983","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0270","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biologicals.2011.05.004","article-title":"Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications","volume":"39","author":"Br\u00f6ker","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0275","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.vaccine.2003.08.003","article-title":"Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccines","volume":"22","author":"Metz","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0280","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1073\/pnas.1201964109","article-title":"Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197","volume":"109","author":"Malito","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0285","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.vaccine.2014.01.047","article-title":"Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines","volume":"32","author":"Pobre","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0290","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1081\/TXR-120014408","article-title":"Structure and function of diphtheria toxin: from pathology to engineering","volume":"21","author":"Chenal","year":"2002","journal-title":"journal of toxicologyToxin Rev."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0295","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1093\/nar\/12.10.4063","article-title":"The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197","volume":"12","author":"Giannini","year":"1984","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0300","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/acs.bioconjchem.8b00661","article-title":"Effects of conformational changes in peptide\u2013CRM197 conjugate vaccines","volume":"30","author":"Jaffe","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0305","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.xphs.2018.03.002","article-title":"Analytical comparability assessments of 5 recombinant CRM197 proteins from different manufacturers and expression systems","volume":"107","author":"Hickey","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0310","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3109\/07388551.2015.1084264","article-title":"Shukla advanced technologies for improved expression of recombinant proteins in bacteria: perspectives and applications","volume":"36","author":"Gupta","year":"2016","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0315","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pep.2011.09.010","article-title":"Reliable protein production in a Pseudomonas fluorescens expression system","volume":"81","author":"Retallack","year":"2012","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0320","article-title":"Efficient recovery of recombinant CRM197 expressed as inclusion bodies in E.coli","volume":"13","author":"Park","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0325","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1093\/emboj\/17.19.5543","article-title":"Disulfide bond formation in the Escherichia coli cytoplasm: an in vivo role reversal for the thioredoxins","volume":"17","author":"Stewart","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0330","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jbiotec.2011.08.024","article-title":"Overexpression and purification of the recombinant diphtheria toxin variant CRM197 in Escherichia coli","volume":"156","author":"Stefan","year":"2011","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2022.102719","article-title":"Cell-free technologies for biopharmaceutical research and production","volume":"76","author":"Zawada","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0340","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1016\/j.vaccine.2021.03.070","article-title":"Non-clinical immunological comparison of a next-generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23)","volume":"39","author":"Fairman","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0350","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/mas.21530","article-title":"Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption\/ionization mass spectrometry: an update for 2013\u20132014","volume":"37","author":"Harvey","year":"2018","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0355","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/2472630319890309","article-title":"Vaccine quality ensured by high-performance anion-exchange chromatography with pulsed amperometric detection","volume":"25","author":"Rohrer","year":"2020","journal-title":"SLAS Technol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0360","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ddtec.2020.11.007","article-title":"Precise protein conjugation technology for the construction of homogenous glycovaccines","volume":"38","author":"Kitowski","year":"2020","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2019.115643","article-title":"Site-selective reactions for the synthesis of glycoconjugates in polysaccharide vaccine development","volume":"230","author":"Lin","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0370","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1039\/C4CS00388H","article-title":"Towards the next generation of biomedicines by site-selective conjugation","volume":"45","author":"Hu","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0375","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1039\/C4SC01361A","article-title":"Deciphering the structure\u2013immunogenicity relationship of anti-Candida glycoconjugate vaccines","volume":"5","author":"Adamo","year":"2014","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0380","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1039\/c3sc51694f","article-title":"Synthesis of a well-defined glycoconjugate vaccine by a tyrosine-selective conjugation strategy","volume":"4","author":"Hu","year":"2013","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0385","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/cbic.201300785","article-title":"Defined conjugation of glycans to the lysines of CRM197 guided by their reactivity mapping","volume":"15","author":"Crotti","year":"2014","journal-title":"ChemBioChem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0390","doi-asserted-by":"crossref","first-page":"20488","DOI":"10.1038\/srep20488","article-title":"Cross reactive material 197 glycoconjugate vaccines contain privileged conjugation sites","volume":"6","author":"M\u00f6ginger","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0395","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.vaccine.2008.01.022","article-title":"Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases","volume":"26","author":"Bardotti","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0400","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/acs.bioconjchem.8b00178","article-title":"Investigation on sugar-protein connectivity in salmonella O-antigen glycoconjugate vaccines","volume":"29","author":"De Benedetto","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0405","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI111976","article-title":"Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197","volume":"76","author":"Anderson","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0410","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0264-410X(98)00348-X","article-title":"Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines","volume":"17","author":"Costantino","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0415","series-title":"Handbook of Meningococcal Disease","first-page":"343","article-title":"Conjugate vaccines","author":"Ravenscroft","year":"2006"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0420","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.vaccine.2004.10.021","article-title":"Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitidis groups Y and W135","volume":"23","author":"Bardotti","year":"2005","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.ijbiomac.2022.07.137_bb0425","first-page":"1808","article-title":"Factors contributing to the immunogenicity of meningococcal conjugate vaccines","volume":"12","author":"Br\u00f6ker","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0430","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161257","article-title":"Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany","volume":"11","author":"van der Linden","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0435","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jinf.2014.06.006","article-title":"Review: current and new generation pneumococcal vaccines","volume":"69","author":"Feldman","year":"2014","journal-title":"J. Infect."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0440","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/11204790-000000000-00000","article-title":"Meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (Menveo\u00ae)","volume":"24","author":"Deeks","year":"2010","journal-title":"BioDrugs"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0445","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/erv.10.147","article-title":"Menveo\u00ae): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y","volume":"10","author":"Cooper","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0455","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/infdis\/jiz062","article-title":"A Novel hexavalent capsular polysaccharide conjugate vaccine (GBS6) for the prevention of neonatal group B streptococcal infections by maternal immunization","volume":"220","author":"Buurman","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.658824","article-title":"Control of streptococcal infections: is a common vaccine target achievable against Streptococcus agalactiae and Streptococcus pneumoniae","volume":"12","author":"Bedeley","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0465","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2147\/IDR.S203454","article-title":"A vaccine against group B Streptococcus: recent advances","volume":"13","author":"Carreras-Abad","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0470","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7774\/cevr.2018.7.1.76","article-title":"Status of group B streptococcal vaccine development","volume":"7","author":"Lin","year":"2018","journal-title":"Clin. Exp. Vaccine Res."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0475","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1016\/j.vaccine.2015.12.072","article-title":"Status of vaccine research and development of vaccines for GBS","volume":"34","author":"Heath","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0480","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12551-021-00791-z","article-title":"Glycoconjugate vaccines against Salmonella enterica serovars and Shigella species: existing and emerging methods for their analysis","volume":"13","author":"Bazhenova","year":"2021","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0485","doi-asserted-by":"crossref","first-page":"24443","DOI":"10.1073\/pnas.2005857117","article-title":"Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM197 conjugate vaccine","volume":"117","author":"Micoli","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0490","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/ijmr.IJMR_1890_17","article-title":"The need & the issues related to new-generation typhoid conjugate vaccines in India","volume":"151","author":"Vashishtha","year":"2020","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0495","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1093\/cid\/ciaa504","article-title":"Review on the recent advances on typhoid vaccine development and challenges ahead","volume":"71","author":"Syed","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0500","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1016\/j.vaccine.2010.01.012","article-title":"Beta-glucan-CRM197 conjugates as candidates antifungal vaccines","volume":"28","author":"Bromuro","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0505","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1084\/jem.20050749","article-title":"A novel glyco-conjugate vaccine against fungal pathogens","volume":"202","author":"Torosantucci","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0510","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.1039\/C5CS00048C","article-title":"Developments and recent advancements in the field of endogenous amino acid selective bond forming reactions for bioconjugation","volume":"44","author":"Koniev","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0515","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.570185","article-title":"Glycoconjugations of biomolecules by chemical methods","volume":"8","author":"Sarkar","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0520","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1517\/17460441.2011.609554","article-title":"The design of semi-synthetic and synthetic glycoconjugate vaccines","volume":"6","author":"Costantino","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0525","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1039\/c3sc50862e","article-title":"Synthetically defined glycoprotein vaccines: current status and future directions","volume":"4","author":"Adamo","year":"2013","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0530","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0161-5890(86)90136-7","article-title":"Viti a molecular model of artificial glycoprotein with predetermined multiple immunodeterminants for gram-positive and gram-negative encapsulated bacteria","volume":"23","author":"Porro","year":"1986","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0535","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1086\/514063","article-title":"Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines","volume":"176","author":"Daum","year":"1997","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0540","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1016\/j.vaccine.2017.09.055","article-title":"Investigating the candidacy of a capsular polysaccharide-based glycoconjugate as a vaccine to combat Haemophilus influenzae type a disease: a solution for an unmet public health need","volume":"35","author":"Cox","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ijbiomac.2022.07.137_bb0545","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1086\/345863","article-title":"Prevention of haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of hib immunization in Brazil","volume":"187","author":"Ribeiro","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0550","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1155\/2015\/613820","article-title":"Invasive disease due to Haemophilus influenzae type A in children in Canada's north: a priority for prevention","volume":"26","author":"Boisvert","year":"2015","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0555","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1016\/j.vaccine.2014.08.056","article-title":"Impact of conjugation chemistry on the immunogenicity of S.Typhimurium conjugate vaccines","volume":"32","author":"Stefanetti","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0560","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.synbio.2016.12.002","article-title":"Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae","volume":"2","author":"Turner","year":"2017","journal-title":"Synth. Syst. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0565","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/BA20020066","article-title":"Evaluation of meningococcal C oligosaccharide conjugate vaccines by size-exclusion chromatography\/multi-angle laser light scattering","volume":"36","author":"Jumel","year":"2002","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0570","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1073\/pnas.1701885114","article-title":"Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide","volume":"114","author":"Carboni","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0575","first-page":"943","article-title":"Evaluation of immune responses to group B streptococcus type III oligosaccharides containing a minimal protective epitope","volume":"221","author":"Carboni","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0580","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1128\/CVI.00122-06","article-title":"Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity","volume":"13","author":"Michon","year":"2006","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0585","doi-asserted-by":"crossref","first-page":"19077","DOI":"10.1073\/pnas.1314476110","article-title":"Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X","volume":"110","author":"Micoli","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0590","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1093\/infdis\/jiz297","article-title":"Eliminating meningococcal epidemics from the African meningitis belt: the case for advanced prevention and control using next-generation meningococcal conjugate vaccines","volume":"220","author":"Alderson","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0595","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1017\/S0950268807008825","article-title":"The changing face of meningococcal disease in West Africa","volume":"135","author":"Greenwood","year":"2007","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0600","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/CVI.00009-07","article-title":"Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation","volume":"14","author":"Fusco","year":"2007","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0605","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.vaccine.2016.01.040","article-title":"Evaluation of the non-toxic mutant of the diphtheria toxin K51E\/E148K as carrier protein for meningococcal vaccines","volume":"34","author":"Pecetta","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0610","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1016\/S0264-410X(99)00092-4","article-title":"Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines","volume":"17","author":"Ravenscroft","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0615","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1016\/j.vaccine.2009.07.036","article-title":"Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages","volume":"27","author":"Br\u00f6ker","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0620","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10719-021-09991-x","article-title":"Molecular modeling provides insights into the loading of sialic acid-containing antigens onto CRM197: the role of chain flexibility in conjugation efficiency and glycoconjugate architecture","volume":"38","author":"Kuttel","year":"2021","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0625","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1128\/IAI.01056-08","article-title":"Capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter jejuni","volume":"77","author":"Monteiro","year":"2009","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0630","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.carres.2012.11.017","article-title":"The design of a capsule polysaccharide conjugate vaccine against Campylobacter jejuni serotype HS15","volume":"366","author":"Bertolo","year":"2013","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0635","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1038\/npjvaccines.2016.17","article-title":"An efficient cell free enzyme-based total synthesis of a meningococcal vaccine candidate","volume":"1","author":"Fiebig","year":"2016","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047039","article-title":"O:2-CRM197 conjugates against Salmonella Paratyphi A","volume":"7","author":"Micoli","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0645","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1128\/IAI.03079-14","article-title":"Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar Typhimurium","volume":"83","author":"Rondini","year":"2015","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0650","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/vaccines8020160","article-title":"GMMA and glycoconjugate approaches compared in mice for the development of a vaccine against Shigella flexneri serotype 6","volume":"8","author":"Raso","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0655","unstructured":"S.J. Freese A. Anderson V. Pavliak K.U. Jansen I.L. Dodge T.D. Scott J.S. Nanra A.K. Prasad B.A. Green , Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions. CA Patent No. 2766418. Publication date 29 March 2016."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0660","doi-asserted-by":"crossref","first-page":"9713","DOI":"10.1021\/ja401410y","article-title":"Immunological evaluation of a synthetic Clostridium difficile oligosaccharide conjugate vaccine candidate and identification of a minimal epitope","volume":"135","author":"Martin","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0665","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/cb300221f","article-title":"Phosphorylation of the synthetic hexasaccharide repeating unit is essential for the induction of antibodies to Clostridium difficile PSII cell wall polysaccharide","volume":"7","author":"Adamo","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0670","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1021\/acschembio.9b00642","article-title":"Synthetic oligosaccharide-based vaccines protect mice from Clostridioides difficile infections","volume":"14","author":"Broecker","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0675","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1021\/acschembio.7b01057","article-title":"Combined chemical synthesis and tailored enzymatic elongation provide fully synthetic and conjugation-ready Neisseria meningitidis serogroup X vaccine antigens","volume":"13","author":"Oldrini","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0680","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.chembiol.2016.09.016","article-title":"A semi-synthetic oligosaccharide conjugate vaccine candidate confers protection against Streptococcus pneumoniae serotype 3 infection","volume":"23","author":"Parameswarappa","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0685","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1021\/acschembio.5b00768","article-title":"Deciphering antigenic determinants of Streptococcus pneumoniae serotype 4 capsular polysaccharide using synthetic oligosaccharides","volume":"11","author":"Geissner","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0690","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf5347","article-title":"A semisynthetic Streptococcus pneumoniae serotype 8 glycoconjugate vaccine","volume":"9","author":"Schumann","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0695","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/IAI.70.9.5107-5114.2002","article-title":"Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197","volume":"70","author":"Mawas","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0700","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1039\/D0SC02230F","article-title":"Chimeric oligosaccharide conjugate induces opsonic antibodies against Streptococcus pneumoniae serotypes 19A and 19F","volume":"11","author":"Sanapala","year":"2020","journal-title":"Chem. Sci."},{"issue":"7","key":"10.1016\/j.ijbiomac.2022.07.137_bb0705","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1515\/pac-2016-0918","article-title":"Synthesis of group B streptococcus type III polysaccharide fragments for evaluation of their interactions with monoclonal antibodies","volume":"89","author":"Cattaneo","year":"2017","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0710","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1002\/chem.202000284","article-title":"Structure-guided design of a group B streptococcus type III synthetic glycan-conjugate vaccine","volume":"26","author":"Oldrini","year":"2020","journal-title":"Chemistry"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0715","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.vaccine.2010.09.018","article-title":"Evaluation of a group a streptococcus synthetic oligosaccharide as vaccine candidate","volume":"29","author":"Kabanova","year":"2010","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.ijbiomac.2022.07.137_bb0720","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1002\/chem.200601743","article-title":"Synthesis and biological evaluation of phosphono analogues of capsular polysaccharide fragments from Neisseria meningitidis A","volume":"13","author":"Torres-Sanchez","year":"2007","journal-title":"Chemistry"},{"issue":"33","key":"10.1016\/j.ijbiomac.2022.07.137_bb0725","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1039\/c2ob25222h","article-title":"Synthesis and preliminary biological evaluation of carba analogues from Neisseria meningitidis a capsular polysaccharide","volume":"10","author":"Gao","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0730","doi-asserted-by":"crossref","first-page":"11224","DOI":"10.1038\/ncomms11224","article-title":"Multivalent display of minimal Clostridium difficile glycan epitopes mimics antigenic properties of larger glycans","volume":"7","author":"Broecker","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0735","first-page":"1014","article-title":"Synthetic lipoteichoic acid glycans are potential vaccine candidates to protect from Clostridium difficile infections","volume":"23","author":"Broecker","year":"2016","journal-title":"CellChem. Biol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0740","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1002\/anie.201301633","article-title":"Plague detection by anti-carbohydrate antibodies","volume":"52","author":"Anish","year":"2013","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0745","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.chembiol.2014.11.016","article-title":"Antigenic potential of a highly conserved Neisseria meningitidis lipopolysaccharide inner core structure defined by chemical synthesis","volume":"22","author":"Reinhardt","year":"2015","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0750","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/07328303.2011.604453","article-title":"Synthesis of laminarin fragments and evaluation of a \u03b2-(1,3) glucan hexasaccaride-CRM 197 conjugate as vaccine candidate against Candida albicans","volume":"30","author":"Adamo","year":"2011","journal-title":"J. Carbohydr. Chem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0755","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1021\/ol048614m","article-title":"A new homobifunctional p-nitro phenyl ester coupling reagent for the preparation of neoglycoproteins","volume":"6","author":"Wu","year":"2004","journal-title":"Org. Lett."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0760","doi-asserted-by":"crossref","first-page":"13353","DOI":"10.1073\/pnas.1811862115","article-title":"Improving vaccines against Streptococcus pneumoniae using synthetic glycans","volume":"115","author":"Kaplonek","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0765","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1002\/1521-3765(20011015)7:20<4411::AID-CHEM4411>3.0.CO;2-T","article-title":"Synthesis of Streptococcus pneumoniae type 3 neoglycoproteins varying in oligosaccharide chain length, loading and carrier protein","volume":"7","author":"Lefeber","year":"2001","journal-title":"Chemistry"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0770","doi-asserted-by":"crossref","first-page":"201706875","DOI":"10.1073\/pnas.1706875114","article-title":"Semisynthetic glycoconjugate vaccine candidate against Streptococcus pneumoniae serotype 5","volume":"114","author":"Lisboa","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.ijbiomac.2022.07.137_bb0775","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1021\/acschembio.0c00360","article-title":"Sequential linkage of carbohydrate antigens to mimic capsular polysaccharides: toward semisynthetic glycoconjugate vaccine candidates against Streptococcus pneumoniae serotype 14","volume":"15","author":"Seco","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0780","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fchem.2020.00258","article-title":"Conjugation of synthetic trisaccharide of Staphylococcus aureus type 8 capsular polysaccharide elicits antibodies recognizing intact bacterium","volume":"8","author":"Zhao","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0785","doi-asserted-by":"crossref","first-page":"13973","DOI":"10.1002\/anie.201700964","article-title":"A semi-synthetic glycoconjugate vaccine candidate for carbapenem-resistant Klebsiella pneumoniae","volume":"56","author":"Seeberger","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0790","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1039\/C9QO00651F","article-title":"Synthesis and immunological studies of group A Streptococcus cell-wall oligosaccharide\u2013streptococcal C5a peptidase conjugates as bivalent vaccines","volume":"6","author":"Zhao","year":"2019","journal-title":"Org. Chem. Front."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0795","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1021\/acs.joc.9b03085","article-title":"Synthesis of the oligosaccharides of Burkholderia pseudomallei and B. mallei capsular polysaccharide and preliminary immunological studies of their protein conjugates","volume":"85","author":"Geng","year":"2020","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0800","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41467-017-00173-8","article-title":"Deciphering minimal antigenic epitopes associated with Burkholderia pseudomallei and Burkholderia mallei lipopolysaccharide O-antigens","volume":"8","author":"Kenfack","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0805","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1039\/C9QO00486F","article-title":"Synthesis of a dimer of the repeating unit of type Ia group B Streptococcus extracellular capsular polysaccharide and immunological evaluations of related protein conjugates","volume":"6","author":"Liao","year":"2019","journal-title":"Org. Chem. Front."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0810","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1039\/C5OB00177C","article-title":"Chemical synthesis of the outer core oligosaccharide of Escherichia coli R3 and immunological evaluation","volume":"13","author":"Shang","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0815","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/cber.19911240539","article-title":"Anticancer agents, 15. squaric acid diethyl ester: a new coupling reagent for the formation of drug biopolymer conjugates. Synthesis of squaric acid ester amides and diamides","volume":"124","author":"Tietze","year":"1991","journal-title":"Chem. Ber."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0820","series-title":"Bacterial Polysaccharides: Methods and Protocols. Methods in Molecular Biology","first-page":"77","article-title":"Conjugation of synthetic oligosaccharides to proteins by squaric acid chemistry","author":"Pfister","year":"2019"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0825","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.carres.2007.10.015","article-title":"Preparation of glycoconjugates by dialkyl squarate chemistry revisited","volume":"343","author":"Ho","year":"2008","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0830","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/cbic.201600699","article-title":"Conjugate vaccines from bacterial antigens by squaric acid chemistry: a closer look","volume":"18","author":"Xu","year":"2017","journal-title":"Chembiochem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0835","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1128\/IAI.00472-08","article-title":"Identification of the smallest structure capable of evoking opsonophagocytic antibodies against streptococcus pneumoniae type 14","volume":"76","author":"Safari","year":"2008","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0840","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.chembiol.2011.03.009","article-title":"A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic","volume":"18","author":"Oberli","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0845","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1002\/1521-3765(20011015)7:20<4411::AID-CHEM4411>3.0.CO;2-T","article-title":"Synthesis of Streptococcus pneumoniae type 3 neoglycoproteins varying in oligosaccharide chain length, loading and carrier protein","volume":"7","author":"Lefeber","year":"2001","journal-title":"Chemistry"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0850","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1128\/IAI.69.7.4698-4701.2001","article-title":"Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice","volume":"69","author":"Benaissa-Trouw","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0855","doi-asserted-by":"crossref","DOI":"10.1039\/C8MD00546J","article-title":"Synthesis and immunogenicity of the Mycobacterium tuberculosis arabinomannan\u2013CRM197 conjugate","author":"Chang","year":"2019","journal-title":"MedChemComm."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0860","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10719-010-9287-0","article-title":"Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: chemical strategies to prepare glycoconjugates with good carbohydrate loading","volume":"27","author":"Cox","year":"2010","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0865","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1021\/acscentsci.1c00656","article-title":"Synthetic pseudaminic-acid-based antibacterial vaccine confers effective protection against Acinetobacter baumannii infection","volume":"7","author":"Wei","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0870","first-page":"1","article-title":"Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines","volume":"6","author":"Anish","year":"2021","journal-title":"Vaccines."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0875","series-title":"Vaccine Protocols. Methods in Molecular MedicineTM","first-page":"153","article-title":"Preparation of polysaccharide-conjugate vaccines","author":"Peeters","year":"2003"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0880","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2021.07.001","article-title":"Glycoconjugation of Shigella flexneri type 2a O-polysaccharide with CRM197 as a potential vaccine candidate for shigellosis","volume":"72","author":"Narayana","year":"2021","journal-title":"Biologicals"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0885","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.vaccine.2010.11.022","article-title":"Vi-CRM 197 as a new conjugate vaccine against Salmonella typhi","volume":"29","author":"Micoli","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0890","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10719-011-9332-7","article-title":"Investigating the potential of conserved inner core oligosaccharide regions of Moraxella catarrhalis lipopolysaccharide as vaccine antigens: accessibility and functional activity of monoclonal antibodies and glycoconjugate derived sera","volume":"28","author":"Cox","year":"2011","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0895","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/iai.65.6.2088-2093.1997","article-title":"Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker","volume":"65","author":"Kossaczka","year":"1997","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0900","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.4161\/hv.29054","article-title":"Vaccines against invasive Salmonella disease: current status and future directions","volume":"10","author":"MacLennan","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0905","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025398","article-title":"Safety, immunogenicity and dose ranging of a new Vi-CRM197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults","volume":"6","author":"van Damme","year":"2011","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0910","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0915","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S1473-3099(18)30400-6","article-title":"Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study","volume":"18","author":"Chen","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0920","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1039\/C7SC04521B","article-title":"A modular synthetic route to size-defined immunogenic Haemophilus influenzae b antigens is key to the identification of an octasaccharide lead vaccine candidate","volume":"9","author":"Baek","year":"2018","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0925","doi-asserted-by":"crossref","first-page":"9596129","DOI":"10.1155\/2020\/9596129","article-title":"The pneumococcal polysaccharide-tetanus toxin native c-fragment conjugate vaccine: the carrier effect and immunogenicity","volume":"2020","author":"Yu","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0930","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10719-020-09930-2","article-title":"Click chemistry compared to thiol chemistry for the synthesis of site-selective glycoconjugate vaccines using CRM197 as carrier protein","volume":"37","author":"Stefanetti","year":"2020","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0935","doi-asserted-by":"crossref","first-page":"9157","DOI":"10.1002\/anie.201302540","article-title":"Synthesis of Neisseria meningitidis serogroup W135 capsular oligosaccharides for immunogenicity comparison and vaccine development","volume":"52","author":"Wang","year":"2013","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0940","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1021\/jacs.8b04078","article-title":"Pseudaminic acid on exopolysaccharide of Acinetobacter baumannii plays a critical role in phage-assisted preparation of glycoconjugate vaccine with high antigenicity","volume":"140","author":"Lee","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0945","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/acscentsci.7b00504","article-title":"Development of an efficacious, semisynthetic glycoconjugate vaccine candidate against Streptococcus pneumoniae serotype 1","volume":"4","author":"Schumann","year":"2018","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0950","doi-asserted-by":"crossref","first-page":"13198","DOI":"10.1002\/anie.201506112","article-title":"Sugar-protein connectivity impacts on the immunogenicity of site-selective salmonella O-antigen glycoconjugate vaccines","volume":"54","author":"Stefanetti","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0955","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10719-014-9559-1","article-title":"Investigating the immunodominance of carbohydrate antigens in a bivalent unimolecular glycoconjugate vaccine against serogroup A and C meningococcal disease","volume":"31","author":"Adamo","year":"2014","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0960","doi-asserted-by":"crossref","unstructured":"F. G. Rocha A. Berges A. Sedra S. Ghod N. Kapoor L. Pill M. E. Davey J. Fairman F. C. Gibson A Porphyromonas gingivalis capsule-conjugate vaccine protects from experimental oral bone loss, Front. Oral Health 2:686402. doi: 10.3389\/froh.2021.686402.","DOI":"10.3389\/froh.2021.686402"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0965","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1042\/BA20000078","article-title":"Solution stability studies of the subunit components of meningococcal C oligosaccharide-CRM197 conjugate vaccines","volume":"33","author":"Ho","year":"2001","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0970","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.vaccine.2014.11.026","article-title":"Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation","volume":"33","author":"Pecetta","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0975","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1039\/D1SC01928G","article-title":"Retaining the structural integrity of disulfide bonds in diphtheria toxoid carrier protein is crucial for the effectiveness of glycoconjugate vaccine candidates","volume":"13","author":"Carboni","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0980","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ijbiomac.2021.08.177","article-title":"Conjugation of zika virus EDIII with CRM197, 8-arm PEG and mannan for development of an effective zika virus vaccine","volume":"190","author":"He","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0985","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10719-010-9295-0","article-title":"Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM197 glycoconjugates","volume":"27","author":"Kabanova","year":"2010","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0990","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/vaccines8040559","article-title":"Possible cross-reactivity between SARS-CoV-2 proteins, CRM197 and proteins in pneumococcal vaccines may protect against symptomatic SARS-CoV-2 disease and death","volume":"8","author":"Root-Bernstein","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijbiomac.2022.07.137_bb0995","article-title":"Synthetic glycans to improve current glycoconjugate vaccines and fight antimicrobial resistance","author":"Bino","year":"2022","journal-title":"Chem. Rev."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022015690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022015690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T09:44:01Z","timestamp":1758879841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813022015690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":197,"alternative-id":["S0141813022015690"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.07.137","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cross reacting material (CRM197) as a carrier protein for carbohydrate conjugate vaccines targeted at bacterial and fungal pathogens","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.07.137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}